Document is current
Any future updates will be listed below
-
Authors
Feng, Yutian
Huynh, Truc T.
Zheng, Yongxiang
Banks, Rebecca L.
Pomper, Martin G.
Vaidyanathan, Ganesan
Zalutsky, Michael R. https://orcid.org/0000-0002-5456-0324
-
Funding
Funding for this research was provided by:
National Cancer Institute (CA184228)
Z-Alpha Therapeutics (Z-Alpha Therapeutics)
- License Information
-
More Information
Article History
Received: 11 June 2025
Accepted: 9 September 2025
First Online: 30 October 2025
Declarations
:
: All animal experiments were approved and performed following the guidelines of the Duke University Institutional Animal Care and Use Committee (IACUC) as described in Protocol A204-21-10 (2024).
: The authors have consent to publish all the data in the manuscript.
: Ganesan Vaidyanathan, Martin Pomper and Michael Zalutsky are co-inventors on a patent related to [ 211 At]YF2, which has been licensed by Z-Alpha Therapeutics, Inc. Martin Pomper and Michael Zalutsky are co-founders of Z-Alpha Therapeutics and are minority shareholders via stock options. No other potential competing interests related to this work are reported.
